-+ 0.00%
-+ 0.00%
-+ 0.00%

Guggenheim Maintains Buy on Damora Therapeutics, Raises Price Target to $60

Benzinga·09/25/2026 13:04:14
Listen to the news
Guggenheim analyst Brad Canino maintains Damora Therapeutics (NASDAQ:DMRA) with a Buy and raises the price target from $40 to $60.